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The SARS‑CoV‑2 pandemic resulted in considerable morbidity and mortality as well as severe 
economic and societal disruptions. Despite scientific progress, true infection severity, factoring both 
diagnosed and undiagnosed infections, remains poorly understood. This study aimed to estimate 
SARS‑CoV‑2 age‑stratified and overall morbidity and mortality rates based on analysis of extensive 
epidemiological data for the pervasive epidemic in Qatar, a country where < 9% of the population 
are ≥ 50 years. We show that SARS‑CoV‑2 severity and fatality demonstrate a striking age dependence 
with low values for those aged < 50 years, but rapidly growing rates for those ≥ 50 years. Age 
dependence was particularly pronounced for infection criticality rate and infection fatality rate. With 
Qatar’s young population, overall SARS‑CoV‑2 severity and fatality were not high with < 4 infections 
in every 1000 being severe or critical and < 2 in every 10,000 being fatal. Only 13 infections in every 
1000 received any hospitalization in acute‑care‑unit beds and < 2 in every 1000 were hospitalized in 
intensive‑care‑unit beds. However, we show that these rates would have been much higher if Qatar’s 
population had the demographic structure of Europe or the United States. Epidemic expansion 
in nations with young populations may lead to considerably lower disease burden than currently 
believed.
The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and 
associated Coronavirus Disease 2019 (COVID-19) continue to be a global health  challenge1. Aside from direct 
implications on morbidity and  mortality1, the pandemic led to severe economic and societal  disruptions2, a 
consequence of the social and physical distancing restrictions imposed to slow SARS-CoV-2 transmission in 
view of its severity and fatality.
One of the most affected countries by this pandemic is Qatar, a peninsula in the Arabian Gulf region with a 
population of 2.8  million3,4. With its unique demographic and residential dwelling structure where 60% of the 
population are expatriate craft and manual workers (CMWs) living in large shared housing  accommodations3,4, 
Qatar experienced a pervasive epidemic with > 60,000 laboratory-confirmed infections per million population 
as of November 23,  20205,6. The epidemic grew rapidly starting from March 2020, peaked in late May 2020, 
then rapidly declined in subsequent weeks, and had been in a stable low-incidence phase up to end of 2020 
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(Supplementary Figure S1). A series of serological studies completed by November 23, 2020 suggested that about 
half of the population have already been  infected6–9.
With a well-resourced public healthcare structure and a centralized and standardized data-capture system 
for all SARS-CoV-2 testing and COVID-19 care, Qatar has one of the most extensive databases to characterize 
this epidemic and its  toll6. In addition to large-scale polymerase chain reaction (PCR) and serological testing, 
multiple population-based PCR and serological surveys have been conducted to  date6–9. As of November 23, 
2020, cumulative overall testing rates exceeded 638,000 per million population for PCR and 105,000 per million 
population for  antibodies10. A comprehensive clinical characterization has also been completed for the hospital-
ized COVID-19 cases through individual chart reviews by trained medical personnel, including infection severity 
classification as per the World Health Organization (WHO)  guidelines11.
Given the pervasive and advanced nature of the epidemic and availability of extensive epidemiological data, 
Qatar provides a unique opportunity to assess the extent of SARS-CoV-2 morbidity and fatality. We aimed in this 
study to estimate the age-stratified and overall infection acute-care and intensive-care-unit (ICU) hospitalization 
rates, infection severity and criticality rates, and infection fatality rate.
Methods
Mathematical model and parameterization. Building on our previously developed SARS-CoV-2 
 models12–18, an age-structured deterministic mathematical model was constructed to describe SARS-CoV-2 
transmission dynamics and disease progression in the population from the epidemic onset up to November 22, 
2020 (Supplementary Figure S2). Susceptible individuals in each age group were at risk of acquiring the infec-
tion based on their infectious contact rate per day, age-specific susceptibility to the infection, and an age-mixing 
matrix defining mixing between individuals in the different age groups. Following a latency period, infected 
individuals developed an infection that either did not require hospitalization, or that required hospitalization in 
an acute-care bed or in an ICU bed. Individuals admitted to an ICU bed had an additional risk for COVID-19 
mortality. The model further included compartments tracking infection severity (asymptomatic/moderate/mild 
infection, severe infection, or critical infection as per WHO severity classification)11. Population movement 
between model compartments was described using a set of coupled nonlinear differential equations (Supple-
mentary Text S1).
The model was parameterized using best available data for SARS-CoV-2 natural history and epidemiology. 
Model parameters, definitions, and justifications can be found in Supplementary Tables S1 and S2. The size and 
demographic structure of the population of Qatar were based on a population census conducted by Qatar’s 
Planning and Statistics  Authority3.
Model fitting and analyses. The model was fitted to extensive time-series and age-stratified data for PCR 
laboratory-confirmed infections, PCR testing positivity rate, antibody testing positivity rate, PCR and serologi-
cal surveys, daily hospital admissions in acute-care and ICU beds, hospital occupancy in acute-care and ICU 
beds, incidence of severe and critical infections as per WHO  classification11, and COVID-19 deaths (further 
details in Supplementary Text S2). A Bayesian method, based on the incremental mixture importance sampling 
with shot-gun  optimization19,20, was used to fit the model to the different data sources and to estimate the mean 
and 95% credible interval (CI) for each estimated parameter (Supplementary Text S2), such as the mean dura-
tion of acute-care hospitalization and the mean duration of ICU-care hospitalization. The model was coded, 
fitted, and analyzed using MATLAB  R2019a21.
Outcome measures. Table 1 provides a listing of each outcome measure estimated in this study, its defini-
tion, and its interpretation. Two sets of outcome measures were generated. The first set includes crude case rates, 
such as the crude case fatality rate, calculated as the cumulative number of a disease outcome (say COVID-19 
death) over the cumulative number of documented (that is PCR laboratory-confirmed) infections.
The second set includes infection rates, such as the infection fatality rate, calculated as the cumulative num-
ber of a disease outcome (say COVID-19 death) over the model-estimated cumulative number of infections, 
documented and undocumented.
Two separate criteria for classifying morbidity were used: one based on actual recorded hospital admission 
(acute-care or ICU) and one based on clinical presentation as per WHO classification of disease severity. While 
the two are overlapping with severe cases typically admitted to acute-care beds, and critically ill cases admitted 
to ICU beds, a significant fraction of mild or moderately ill cases were hospitalized out of caution. Moreover, 
hospitalization was used as a form of case isolation earlier in the epidemic. Of note that the health system in 
Qatar remained well within its threshold even at the epidemic peak towards end of May 2020.
The diagnosis (detection) rate was further calculated as the cumulative number of infections that were docu-
mented (that is with PCR laboratory-confirmed diagnosis) over the model-estimated cumulative number of 
infections, documented and undocumented.
Ethical approvals. This study was approved by the HMC and Weill Cornell Medicine-Qatar Institutional 
Review Boards.
Results
Figure 1A shows the crude case acute-care and ICU bed hospitalization rate versus time from the epidemic onset 
up to November 22, 2020. The rate was rather stable, but with a slightly declining trend, and was assessed at 113.9 
acute-care and/or ICU hospital admissions per 1000 laboratory-confirmed infections on November 22, 2020. As 
of this date, a total of 18,509 acute-care and 1759 ICU hospital admissions had been registered.
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Figure 1B shows the crude case severity and criticality rate versus time. The rate was rather stable, but with a 
slightly declining trend, and was assessed at 28.0 severe and/or critical cases per 1000 laboratory-confirmed infec-
tions on November 22, 2020. As of this date, a total of 4127 severe and 863 critical infections had been registered.
Figure 1C shows the crude case fatality rate versus time. The rate increased over time, as expected with the 
weeks-long delay between infection and eventual COVID-19 death, but then stabilized as the epidemic entered 
its low but stable infection incidence phase (Supplementary Figure S1). The rate was assessed at 13.2 deaths per 
10,000 laboratory-confirmed infections on November 22, 2020. As of this date, a total of 235 COVID-19 deaths 
had been registered.
The model produced robust fits to each dataset. Supplementary Table S3 summarizes the goodness-of-fit. 
Supplementary Figures S3–S7 show the age-specific posterior distributions of the infection acute-care bed hos-
pitalization rate (Supplementary Figure S3), infection ICU bed hospitalization rate (Supplementary Figure S4), 
infection severity rate (Supplementary Figure S5), infection criticality rate (Supplementary Figure S6), and infec-
tion fatality rate (Supplementary Figure S7). Meanwhile, Supplementary Figures S8–S9 show the overall (total 
population of all age groups) infection acute-care bed hospitalization rate (Supplementary Figure S8A), infection 
ICU bed hospitalization rate (Supplementary Figure S8B), infection severity rate (Supplementary Figure S8C), 
infection criticality rate (Supplementary Figure S8D), and infection fatality rate (Supplementary Figure S9).
Table 2, Figs. 2, and 3A show the estimated mean and 95% CI of all age-specific infection rate measures. 
All rates showed very strong age dependence. Measures increased steadily with age, with low values for 
those < 50 years of age, but very rapidly growing rates for those ≥ 50 years of age. The strong age dependence was 
even more pronounced for infection ICU bed hospitalization rate (Fig. 2B), infection criticality rate (Fig. 2D), 
and infection fatality rate (Fig. 3A).
The overall (total population of all age groups) infection acute-care bed hospitalization rate was estimated at 
13.10 (95% CI 12.82–13.24) per 1000 infections, infection ICU bed hospitalization rate at 1.60 (95% CI 1.58–1.61) 
per 1000 infections, infection severity rate at 3.06 (95% CI 3.01–3.10) per 1000 infections, infection criticality 
rate at 0.68 (95% CI 0.67–0.68) per 1000 infections, and infection fatality rate at 1.85 (95% CI 1.74–1.95) per 
10,000 infections.
Applying the above estimated age-specific infection fatality rate in Qatar to the age structure of other national 
 populations22, the overall infection fatality rate for these countries varied substantially just because of the differ-
ences in the demographic structure (Fig. 3B).
Figure 1D shows the infection acute-care and ICU bed hospitalization rate versus time. The rate increased over 
time, as expected with the delay between infection and hospital admission, unlike the corresponding crude case 
Table 1.  Crude case rates and infection rates estimated in this study. *Per World Health Organization (WHO) 
infection severity  classification11.
Outcome measure Definition Interpretation
Crude case rates-data estimation
1. Crude acute-care and ICU bed hospitalization rate
Cumulative number of hospital admissions into acute-care 
or ICU beds over the cumulative number of documented 
PCR laboratory-confirmed infections
Proportion of PCR laboratory-confirmed infections that 
progressed to hospital admission into acute-care or ICU 
beds
2. Crude case severity and criticality rate
Cumulative number of COVID-19 severe or critical infec-
tions* over the cumulative number of documented PCR 
laboratory-confirmed infections
Proportion of PCR laboratory-confirmed infections that 
progressed to become severe or critical
3. Crude case fatality rate
Cumulative number of COVID-19 deaths over the cumula-
tive number of documented PCR laboratory-confirmed 
infections
Proportion of PCR laboratory-confirmed infections that 
ended in COVID-19 death
Infection rates-model estimation
1. Infection acute-care bed hospitalization rate
Cumulative number of hospital admissions into acute-care 
beds over the cumulative number of infections, documented 
and undocumented
Proportion of infections that progressed to acute-care bed 
hospital admission
2. Infection ICU bed hospitalization rate
Cumulative number of hospital admissions into ICU beds 
over the cumulative number of infections, documented and 
undocumented
Proportion of infections that progressed to ICU bed hospi- 
tal admission
3. Infection severity rate
Cumulative number of COVID-19 severe infections* over 
the cumulative number of infections, documented and 
undocumented
Proportion of infections that progressed to become severe 
infections
4. Infection criticality rate
Cumulative number of COVID-19 critical infections* over 
the cumulative number of infections, documented and 
undocumented
Proportion of infections that progressed to become critical 
infections
5. Infection fatality rate Cumulative number of COVID-19 deaths over the cumula-tive number of infections, documented and undocumented Proportion of infections that ended in COVID-19 death
Combined infection rates-model estimation
1. Infection acute-care and ICU bed hospitalization rate
Cumulative number of admissions into acute-care or ICU 
beds over the cumulative number of infections, documented 
and undocumented
Proportion of infections that progressed to acute-care or 
ICU bed hospital admission
2. Infection severity and criticality rates
Cumulative number of COVID-19 severe or critical 
infections* over the cumulative number of infections, 
documented and undocumented
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Figure 1.  Temporal trend in (A) crude case acute-care and ICU bed hospitalization rate, (B) crude case severity 
and criticality rate, (C) crude case fatality rate, (D) infection acute-care and ICU bed hospitalization rate, (E) 
infection severity and criticality rate, and (F) infection fatality rate. Classification of infection severity and 
criticality was per WHO infection severity  classification11.
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rate which decreased over time as PCR testing was expanded and more and more of the mild and asymptomatic 
infections were diagnosed. The infection acute-care and ICU bed hospitalization rate then stabilized (Fig. 1D) 
as the epidemic peaked and started to decline (Supplementary Figure S1). The rate was assessed at 13.8 hospital 
admissions per 1000 infections on November 22, 2020. A similar pattern was found for the infection severity and 
Table 2.  Estimated mean and 95% credible interval (CI) of the age-specific infection acute-care and ICU 
bed hospitalization rates, infection severity and criticality rates, and infection fatality rate.  Classification of 
infection severity and criticality was per WHO infection severity  classification11.
Age group (years)
Infection acute-care bed 
hospitalization rate (per 
1000 infections)
Infection ICU bed 
hospitalization rate (per 
1000 infections)
Infection severity rate (per 
1000 infections)
Infection criticality rate (per 
1000 infections)
Infection fatality rate (per 
10,000 infections)
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
0–9 8.06 (7.85–8.20) 0.44 (0.43–0.46) 0.07 (0.07–0.08) 0.00 (0.00–0.00) 0.00 (0.00–0.00)
10–19 7.15 (6.96–7.27) 0.39 (0.38–0.41) 0.13 (0.13–0.13) 0.04 (0.04–0.04) 0.00 (0.00–0.00)
20–29 7.19 (7.02–7.28) 0.40 (0.39–0.41) 0.47 (0.46–0.48) 0.08 (0.08–0.08) 0.12 (0.11–0.13)
30–39 10.07 (9.88–10.18) 0.71 (0.69–0.72) 1.86 (1.83–1.89) 0.21 (0.21–0.21) 0.09 (0.09–0.10)
40–49 16.00 (15.65–16.17) 1.92 (1.90–1.94) 4.05 (3.99–4.11) 0.73 (0.72–0.73) 0.75 (0.70–0.80)
50–59 26.35 (25.69–26.68) 4.67 (4.63–4.70) 8.35 (8.22–8.48) 2.10 (2.08–2.12) 5.31 (4.99–5.65)
60–69 60.46 (58.82–61.53) 12.65 (12.54–12.75) 25.08 (24.70–25.48) 7.43 (7.37–7.49) 27.68 (26.15–29.26)
70–79 99.84 (97.23–101.65) 38.03 (37.72–38.32) 50.16 (49.39–50.95) 22.45 (22.25–22.62) 116.44 (110.43–122.83)
80 + 36.73 (35.76–37.37) 32.94 (32.60–33.26) 31.26 (30.78–31.76) 23.02 (22.82–23.19) 175.76 (168.92–183.17)
Overall population 13.10 (12.82–13.24) 1.60 (1.58–1.61) 3.06 (3.01–3.10) 0.68 (0.67–0.68) 1.85 (1.74–1.95)
Figure 2.  The age-specific (A) infection acute-care bed hospitalization rate, (B) infection ICU bed 
hospitalization rate, (C) infection severity rate, and (D) infection criticality rate. Classification of infection 
severity and criticality was per WHO severity  classification11.
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criticality rate (Fig. 1E) and infection fatality rate (Fig. 1F), which were assessed at 3.4 cases per 1000 infections 
and 1.6 deaths per 10,000 infections, respectively, on November 22, 2020.
The study generated other relevant estimates. The diagnosis (detection) rate as of November 22, 2020, that 
is the proportion of infections that were documented out of all infections that were estimated to have occurred, 
was assessed at 12.1% (95% CI 12.0–12.1%). The mean duration of acute-care hospitalization was estimated at 
8.73 (95% CI 8.62–8.83) days and the mean duration of ICU hospitalization was estimated at 12.30 (95% CI 
12.18–12.41) days.
Discussion
The striking finding of this study is that SARS-CoV-2 morbidity and mortality demonstrated a very strong age 
dependence. Infection severity, criticality, and fatality increased very rapidly with age, apart for those ≥ 80 years 
of age possibly because of a survival effect. This was particularly the case for infection criticality and fatality 
which were limited for those < 50 years of age but increased very rapidly for those ≥ 50 years of age (Figs. 2, 3). 
This strong age dependence combined with the lower infection exposure in those ≥ 60 years of age (Supplemen-
tary Figure S10) and the small proportion of the population ≥ 50 years of age (9%) and ≥ 60 years of age (2%), all 
contributed together to a low morbidity and mortality in Qatar. Out of every 1000 infections, only 3.7 infections 
were destined to be severe or critical, and out of every 10,000 infections, only 1.9 infections were destined to 
end in COVID-19 death (Table 2).
Notably, both SARS-CoV-2 morbidity and mortality in Qatar were not much higher than those typically 
seen in a seasonal influenza epidemic in the United  States23,24. This fact, however, needs to be interpreted in 
context. With the young age structure of the population in Qatar, a seasonal influenza epidemic in this country 
has a much lower severity than that in the United States. Typically, only a handful of influenza-related deaths 
are reported every year in  Qatar25.
Figure 3.  (A) The age-specific infection fatality rate in Qatar. (B) Estimated overall (total population of all 
age groups) infection fatality rate for several select countries that are characterized by diverse demographic 
structures. The estimates were generated by applying the Qatar-estimated age-specific infection fatality rate to the 
age structure of the population in each country. Population size and demographic age-structure of each country 
were extracted from the United Nations World Population Prospects  database22.
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Other lines of evidence support these findings. In a survey of ten CMW communities in Qatar, only five severe 
infections and one critical infection ever occurred in 3233 persons with confirmed infection (antibody and/or 
PCR positive result), that is an infection severity and criticality rate of 2.5 (95% CI 1.1–4.9) per 1000  infections8. 
In another nationwide survey of the CMW population, only seven severe infections and one critical infection 
ever occurred in 1590 persons with antibody and/or PCR positive result, an infection severity and criticality 
rate of 5.0 (95% CI 2.2–9.9) per 1000  infections9. Both of these estimates are in agreement with the present study 
estimate of 3.7 (95% CI 3.7–3.8) per 1000 infections.
These figures, however, are substantially lower than those estimated elsewhere, often using early epidemic 
 data26–34. For instance, the infection acute-care and ICU bed hospitalization rate and the infection fatality rate 
were estimated at 20.4 per 1000 infections and 65.0 per 10,000 infections in the United States,  respectively32. 
The fact that the early phases of the epidemic in Europe and the United States heavily affected nursing facilities 
and care homes of the elderly may have biased many of the early estimates to higher values. It is also possible 
that our estimates are lower because of the robust accounting of the large pool of undocumented infections 
in the present study, thanks to the series of serological surveys conducted in  Qatar6–9. These surveys provided 
some of the key input data for this modeling study. For instance, the nationwide survey of the CMW population 
found that only 9.3% (95% CI 7.9–11.0%) of those antibody positive had a prior documented PCR laboratory-
confirmed  infection9. This is in agreement with the diagnosis (detection) rate estimated here at 12.1% (95% CI 
12.0–12.1%), as well as growing evidence from other countries indicating that only one in every 10 infections 
was ever diagnosed during the epidemic’s first  wave26,35–38. The totality of evidence on the Qatar epidemic also 
indicates that most infections were asymptomatic or minimally mild to be  diagnosed5–9,39–41. For instance, a 
national SARS-CoV-2 PCR survey found that 58.5% of those testing PCR positive reported no symptoms within 
the preceding two weeks of the  survey6.
In light of these findings, it is evident that the strong age dependence of SARS-CoV-2 morbidity and mortality 
is a principal contributor to the low morbidity and mortality seen in Qatar compared to elsewhere. The impact 
of this strong age dependence is illustrated in Fig. 3B where the age-specific infection fatality rate of Table 2 has 
been applied to the age structure of other national  populations22. The infection fatality rate in Italy was found 
to be tenfold higher than that in Qatar, only because of the population’s different age structure. These findings 
indicate that the infection morbidity and mortality may vary immensely across countries, and will be substantially 
lower in countries with younger demographic structures, as suggested  earlier12.
While age appears to be the principal factor, other factors could have also contributed to explaining the 
low morbidity and mortality in Qatar. Evidence indicates T cell and antibody reactivity against SARS-CoV-2 
in unexposed  individuals42–45, that probably reflects development of T cell and antibody immune memory to 
circulating ‘common cold’ coronaviruses, which may have in turn led to lower morbidity and  mortality42–45. 
The shared-housing dwelling structure in Qatar that contributed to the large SARS-CoV-2 epidemic may have, 
along with the frequent international travel of Qatar’s expatriate population, also contributed to higher levels 
of exposure to other common cold  coronaviruses46,47, thereby inducing high levels of broadly cross-reactive T 
cell and antibody responses. Such pre-existing immune  reactivity42–45 may have thus resulted in lower levels of 
SARS-CoV-2 morbidity and mortality in the population of Qatar.
The resourced healthcare system, which was well below its threshold even at the epidemic peak, may have also 
contributed to the low observed morbidity and mortality. Emphasis on proactive early hospital admission and 
treatment, in addition to a cautious approach for SARS-CoV-2 case management, may have limited the number 
of people who went on to progress to severe or critical disease. This is illustrated in comparing the hospitalization 
rate in Qatar versus that in the United States, 13.1 versus 20.432 per 1000 infections, and the infection fatality rate, 
1.9 versus 65.032 per 10,000 infections, respectively. Though the infection fatality rate was much lower in Qatar, 
the hospitalization rate was not too different in the two countries. The cautious approach in Qatar that empha-
sized hospitalization of COVID-19 patients even when this was not indicated per guidelines may have facilitated 
provision of medical care promptly when COVID-19 cases started to progress to more severe forms of disease.
Limitations may have affected this study. We estimated rates of infection morbidity and mortality, not 
accounting for potential differences by sex, comorbidities, or other factors. Model estimations are contingent 
on the validity and generalizability of input data. Available input data were most complete at the national level, 
and although there could be subpopulation differences in the highly diverse population of Qatar, these could not 
be factored in the model given insufficient data at the subpopulation level. Despite these limitations, our model, 
tailored to the complexity of the epidemic in Qatar, was able to reproduce the observed epidemic trends, and 
provided profound insights about healthcare needs and infection morbidity and mortality.
In conclusion, SARS-CoV-2 morbidity and mortality demonstrate a strikingly strong age dependence. With 
its young population structure, both morbidity and mortality were low in Qatar, and not much higher than those 
typically seen in a seasonal influenza epidemic in the United  States23,24, but they were substantially lower than 
COVID-19 morbidity and mortality rates in the United States and  elsewhere32–34. Out of every 1000 infections, 
only 3.7 infections were severe or critical, and out of every 10,000 infections, only 1.9 infections were fatal. How-
ever, these rates would have been much higher if the population of Qatar had a similar demographic structure 
to that found in Europe or the United States. These findings suggest that SARS-CoV-2 morbidity and mortality 
may vary immensely by country or region, and that the pandemic expansion in nations with young populations 
may lead to considerably milder disease burden than currently believed.
Data availability
All data are available within the manuscript and its supplementary materials.
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